drugset / Trial / NCT02564029

PF-06372865 in Subjects With Photosensitive Epilepsy

NCT02564029

Phase 2 Completed 7 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

PF-06372865 in subjects with photosensitive epilepsy

Timeline

Start
2015-12-16
Primary completion
2017-01-10
Completion
2017-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Darigabat Small molecule 17.5 mg
Subject Darigabat Small molecule 52.5 mg
Comparator Lorazepam Small molecule 2 mg Oral